Hidradenitis Suppurativa

Initial phase 2 data show abdakibart (AVTX-009) boosts HiSCR responses in moderate to severe HS, with favorable safety, paving way for phase 3.

Building trust through empathetic communication, education, and support resources is essential to improving outcomes for patients with HS.

Steven Daveluy, MD, discusses how this approval helps close a critical gap in care for adolescents living with HS.

The small protein therapeutic gave hidradenitis suppurativa patients greater reductions in inflammatory lesion counts after 32 weeks.

Three-year BE HEARD EXT data confirm that bimekizumab's clinical responses deepen over time, with HiSCR90 rates rising from 42% at year 1 to 64% at year 3.

Panelists discuss the role of communication, follow-up, and safety monitoring in optimizing long-term biologic therapy outcomes.

BE HEARD extension data underscore the importance of early diagnosis and treatment initiation to optimize long-term outcomes in hidradenitis suppurativa.

Panelists discuss the role of communication, follow-up, and safety monitoring in optimizing long-term biologic therapy outcomes.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, reviewed clinical trial and long-term data supporting biologic therapies for HS, emphasizing individualized patient selection and timing of intervention.

Experts discuss how clinicians identify the right moment to transition from conventional therapy to biologic treatment in patients with hidradenitis suppurativa (HS).

Novartis secured the approval through a pharmacokinetic extrapolation strategy rather than a full pediatric RCT, leveraging adult HS trial data and existing pediatric PK modeling from other approved indications.

This FAQ answers top questions of HS therapy: when to escalate to biologics, add surgery, measure success, and support mental health.

A qualitative study found that hidradenitis suppurativa (HS) significantly influences patients’ daily decisions, emotional health, relationships, and financial stability.

The final case described a young woman with clinically mild hidradenitis suppurativa (HS) but significant emotional and social distress, prompting some of the most passionate discussion across the 3 roundtables.

This case involved a young patient with mild to moderate hidradenitis suppurativa (HS) of the axillae, characterized by intermittent, limited lesions without tunneling or scarring. Although seemingly routine, it prompted deeper reflection.

The first case involved a middle-aged patient with severe, long-standing hidradenitis suppurativa (HS) marked by years of active disease with extensive sinus tracts, dense scarring, chronic drainage, frequent flares, constant pain, limited mobility, and a daily life centered around symptom management.

Modern hidradenitis suppurativa (HS) management prioritizes restoration of function and quality of life, not just reduction in lesion counts, according to Barry Resnik, MD.

UCB shares 3-year BIMZELX (bimekizumab) data in HS, showing sustained hidradenitis suppurativa lesion clearance and major severity reductions.

Explore the long-term efficacy of biologics for HS, highlighting bimekizumab's superior outcomes in managing this chronic condition.

Explore the nuanced experiences of drainage in hidradenitis suppurativa (HS), revealing its profound physical and psychological impacts on patients' lives.

Firas G. Hougeir, MD, and clinician attendees discussed how to use real-world patient scenarios to determine optimal timing for biologic initiation for patients with moderate to severe HS.

Topical roflumilast 0.3% cream shows promise in reducing lesions and symptoms of mild hidradenitis suppurativa (HS), offering a well-tolerated treatment option.

Explore the complexities of managing hidradenitis suppurativa (HS) through real-world case studies moderated by Afsaneh Alavi, MD.

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.